Immunologic Factor
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Due to Rare Adverse Event
Novavax, FDA, COVID-19, Influenza, Vaccine, Clinical Hold, Motor Neuropathy
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial
Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results
Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants
Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.
FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer
FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab
Bavarian Nordic’s Mpox Vaccine Demonstrates Equivalent Efficacy in Teens and Adults: NIH Study
Mpox vaccine, Bavarian Nordic, MVA-BN vaccine, Teenagers, Adults, Antibody response, Safety, Efficacy, NIH study
Eisai to Seek Reconsideration of TGA’s Initial Decision on Lecanemab for Alzheimer’s Disease in Australia
Lecanemab, Alzheimer’s disease, Therapeutic Goods Administration (TGA), Eisai, Biogen, reconsideration, Australia
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Standalone Influenza Vaccine Trials
Novavax, FDA, Clinical Hold, COVID-19, Influenza, Vaccine Trials, Motor Neuropathy
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales
Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial